Skip to main content
SpringerLink
Log in
Book cover

Myeloma Therapy pp 57–76Cite as

Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics

  • Chapter

  • 585 Accesses

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): Consensus statement. Mayo Clin Proc. 2007;82:323–341.

    Article  PubMed  CAS  Google Scholar 

  2. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113:73–77.

    Article  PubMed  CAS  Google Scholar 

  3. Debes-Marun C, Dewald G, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427–436.

    Article  PubMed  CAS  Google Scholar 

  4. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical Significance of Cytogenetic Studies in 100 Patients With Multiple Myeloma, Plasma Cell Leukemia, or Amyloidosis. Blood. 1985;66:380–390.

    PubMed  CAS  Google Scholar 

  5. Sawyer JR, Waidron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41–49.

    Article  PubMed  CAS  Google Scholar 

  6. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;l4)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics. 1997;16:260–264.

    Article  PubMed  CAS  Google Scholar 

  7. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 1 lq and not with other karyotype abnormalities. Blood. 1995;86:4250–4256.

    PubMed  CAS  Google Scholar 

  8. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia. 1998;12:960–969.

    Article  PubMed  CAS  Google Scholar 

  9. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562–2567.

    Article  PubMed  CAS  Google Scholar 

  10. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes, Chromosomes & Cancer. 2003;38:234–239.

    Article  Google Scholar 

  11. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106:2156–2161.

    Article  PubMed  CAS  Google Scholar 

  12. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with mono-clonalgammopathy of undetermined significance. Blood. 1995;86:3915–3921.

    PubMed  CAS  Google Scholar 

  13. Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: Chromosome changes are a common finding within bone marrow plasma cells. Br. J. Haematol. 1995;90:693–696.

    Article  PubMed  CAS  Google Scholar 

  14. Bergsagel PL, Chesi M, Brents LA, et al. Translocations into IgH switch regions — the genetic hallmark of multiple myeloma. Blood. 1995;86:223.

    Google Scholar 

  15. Bergsagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immu-noglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. USA. 1996;93(24):13931–13936.

    Article  PubMed  CAS  Google Scholar 

  16. Jalal SM, Law ME. Utility of multicolor fluorescent in situ hybridization in clinical cytogenetics. Genet Med. 1999;1:181–186.

    Article  PubMed  CAS  Google Scholar 

  17. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822–825.

    Article  PubMed  CAS  Google Scholar 

  18. Rao PH, Cigudosa JC, Ning Y, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood. 1998;92:1743–1748.

    PubMed  CAS  Google Scholar 

  19. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575.

    Article  PubMed  CAS  Google Scholar 

  20. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489–3495.

    Article  PubMed  CAS  Google Scholar 

  21. Tabernero D, San Miguel JF, Garcia-Sanz M, et al. Incidence of chromosome numerical changes in multiple myeloma: Fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am. J. Pathol. 1996;149:153–161.

    PubMed  CAS  Google Scholar 

  22. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:3854–3859.

    PubMed  CAS  Google Scholar 

  23. Ahman GJ, Jalal SM, Juneau AL, et al. A Novel Three-Color, Clone-specific Fluorescence In situ Hybridization Procedure for Monoclonal Gammopathies. Cancer Genet Cytogenet. 1998;101:7–11.

    Article  Google Scholar 

  24. Kallioniemi OP, Kallioniemi A, Sudar D, et al. Comparative genomic hybridization: A rapid new method for detecting and mapping DNA amplification in tumors. Semin Cancer Biol. 1993;4:41–6.

    PubMed  CAS  Google Scholar 

  25. Carrasco DR, Tonon U, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313–325.

    Article  PubMed  CAS  Google Scholar 

  26. Avet-Loiseau H, Bataille R. Detection of nonrandom chromosomal changes in multiple myeloma by comparative genomic hybridization. Blood. 1998;92: 2997–2998.

    PubMed  CAS  Google Scholar 

  27. Rao PH. Comparative genomic hybridization for analysis of changes in DNA copy number in multiple myeloma. Methods in Molecular Medicine. 2005;113:71–83.

    PubMed  CAS  Google Scholar 

  28. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 1998;20:207–211.

    Article  PubMed  CAS  Google Scholar 

  29. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanoni-cal NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–144

    Article  PubMed  CAS  Google Scholar 

  30. Bergsagel PL, Kuehi WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333–6338.

    Article  PubMed  CAS  Google Scholar 

  31. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925–1930.

    PubMed  CAS  Google Scholar 

  32. Dao DD, Sawyer JR, Epstein J, et al. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia. 1994;8:1280–1284.

    PubMed  CAS  Google Scholar 

  33. Avet-Loiseau H, Daviet A, Sauner S, et al. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol. 2000;111:1116–1117.

    Article  Google Scholar 

  34. Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981–986.

    Article  PubMed  CAS  Google Scholar 

  35. Fonseca R, Harrington D, Oken M, et al. Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (A 13) in multiple myeloma: An Eastern Cooperative Oncology Group (ECOG) Study. Cancer Research. 2002;62:715–720.

    PubMed  CAS  Google Scholar 

  36. Avet-Loiseau H, Li JY, Morineau N, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood. 1999;94:2583–2589.

    PubMed  CAS  Google Scholar 

  37. Shaughnessy J, Tian E, Sawyer J,. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505–1511.

    PubMed  CAS  Google Scholar 

  38. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424.

    PubMed  CAS  Google Scholar 

  39. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008–4010.

    PubMed  CAS  Google Scholar 

  40. Fassas AB, Tricot G. Chromosome 13 deletionlhypodiploidy and prognosis in multiple myeloma patients. Leukemia & Lymphoma. 2004;45:1083–1091.

    Article  CAS  Google Scholar 

  41. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101:189–194.

    Article  PubMed  CAS  Google Scholar 

  42. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphasedefined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood. 2003;101:3849–3856.

    Article  PubMed  CAS  Google Scholar 

  43. Shaughnessy J, Jr., Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. British Journal of Haematology. 2003;120:44–52.

    Article  PubMed  Google Scholar 

  44. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566–1571.

    Article  PubMed  CAS  Google Scholar 

  45. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood. 1998;91:3366–3371.

    PubMed  CAS  Google Scholar 

  46. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–1617.

    Article  PubMed  CAS  Google Scholar 

  47. Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106:3553–3558.

    Article  PubMed  CAS  Google Scholar 

  48. Tricot G, Sawyer JIR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659–2666.

    PubMed  CAS  Google Scholar 

  49. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4; 14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21:143–150.

    Article  PubMed  CAS  Google Scholar 

  50. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyper-diploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20:807–813.

    Article  PubMed  CAS  Google Scholar 

  51. Chang H, Trieu Y, Qi X, X u W Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2007;31:779–782.

    Article  PubMed  CAS  Google Scholar 

  52. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Kuenburg E, Wieser R, Zielinski C, Drach J. Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007;21:164–168.

    Article  PubMed  CAS  Google Scholar 

  53. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–157.

    Article  PubMed  CAS  Google Scholar 

  54. Mateos MV, Hernandez JIM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase I/H study. Blood. 2006;108:2165–2172.

    Article  PubMed  CAS  Google Scholar 

  55. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–5622.

    Article  PubMed  CAS  Google Scholar 

  56. Nishida K, Tamura A, Nakazawa N, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1997;90:526–534.

    PubMed  CAS  Google Scholar 

  57. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunological Reviews. 2003;194:96–104.

    Article  PubMed  CAS  Google Scholar 

  58. Bergsagel PL, Kuehi WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303.

    Article  PubMed  CAS  Google Scholar 

  59. Dalton WS, Bergsagel PL, Kuehl WM, et al. Multiple Myeloma. Hematology Am Soc Hematol Educ Program. 2001;157–177.

    Google Scholar 

  60. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehi W M Dysregulation of cyclin Dl by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674–681.

    PubMed  CAS  Google Scholar 

  61. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(1 1;14)(q13;q32): A report on 13 cases. Br J Haematol. 1998;101:296–301.

    Article  PubMed  CAS  Google Scholar 

  62. Harrison C, Mazullo H, Cheung K, et al. Chromosomal abnormalities in systemic amyloidosis. Proceedings of the VIII International Myeloma Workshop. Banff, Alberta, Canada; 2001:P18.

    Google Scholar 

  63. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001;98:2266–2268.

    Article  PubMed  CAS  Google Scholar 

  64. Garand R, Avet-Loiseau H, Accard F, et al. t(11; 14) and t(4; 14) translocations correlated with mature lymphoplasmocytoid and immature morphology, respectively, in multiple myeloma. Leukemia. 2003;17:2032–2035.

    Article  PubMed  CAS  Google Scholar 

  65. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11; 1 4)(q 13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735–3741.

    Article  PubMed  CAS  Google Scholar 

  66. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition some plasma cell tumors. Blood. 2005;105:317–323.

    Article  PubMed  CAS  Google Scholar 

  67. GertzMA, LacyMQ, DispenzieriA,etal. Clinical implicationsoft(11;14)(q13;q32), t(4;14)(p16.3;q32), and -Ylpl3 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837–2840.

    Article  PubMed  CAS  Google Scholar 

  68. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579–1583.

    Article  PubMed  CAS  Google Scholar 

  69. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520–1529.

    Article  PubMed  CAS  Google Scholar 

  70. Avet-Loiseau H, Facon T, Daviet A, et al. 1 4q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a mul-tistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59:4546–4550.

    PubMed  CAS  Google Scholar 

  71. FonsecaR,OkenMM,GreippPR,EasternCooperativeOncologyGroupMyelomaG The t(4; l4.)(pl6.3;q3 2) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal of undetermined significance. Blood. 2001;98:1271–1272.

    Article  PubMed  CAS  Google Scholar 

  72. Chang H, Qi XY, Samiee S, et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005;36:793–796.

    Article  PubMed  CAS  Google Scholar 

  73. Chang H, Trieu Y, Qi X, et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2006;31:779–782.

    Article  PubMed  Google Scholar 

  74. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177–3188.

    Article  PubMed  CAS  Google Scholar 

  75. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105: 2941–2948.

    Article  PubMed  CAS  Google Scholar 

  76. Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001 is cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006;107:4039–4046.

    Article  PubMed  CAS  Google Scholar 

  77. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 1 6q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91:4457–4463.

    PubMed  CAS  Google Scholar 

  78. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.

    Article  PubMed  CAS  Google Scholar 

  79. Shaughi-iessy J, Jr., Gabrea A, Qi Y, et al. Cyclin D3 at 6p2l is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98:217–223.

    Article  Google Scholar 

  80. Drach J, Ackermann J, Kromer E, et al. Short survival of Patients with Multiple Myeloma and p53 gene deletion: A study by Interphase FISH. Blood. 1997;90:244a.

    Google Scholar 

  81. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–809.

    PubMed  CAS  Google Scholar 

  82. Avet-Loiseau H, Li JY, Godon C, et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106:717–719.

    Article  PubMed  CAS  Google Scholar 

  83. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358–360.

    Article  PubMed  CAS  Google Scholar 

  84. Tiedemann RR, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008; 22:1044–1052.

    Article  PubMed  CAS  Google Scholar 

  85. Chng WJ, Price-Troska T, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21:582–584.

    Article  PubMed  CAS  Google Scholar 

  86. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1 q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91:1732–1741.

    PubMed  CAS  Google Scholar 

  87. Zhan F, Colla S, Wu X, et al. CKS1B, over expressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip 1-depend-ent and independent mechanisms. Blood. 2007;109:4995–5001.

    Article  PubMed  CAS  Google Scholar 

  88. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034–2040.

    Article  PubMed  CAS  Google Scholar 

  89. Shaughnessy JD, Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–2284.

    Article  PubMed  CAS  Google Scholar 

  90. Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol. 2006;135:486–491.

    Article  PubMed  CAS  Google Scholar 

  91. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res. 2004;64:1546–1558.

    Article  PubMed  CAS  Google Scholar 

  92. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529–534.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, Scottsdale, AZ, USA

    Esteban Braggio, Michael Sebag & Rafael Fonseca

Authors
  1. Esteban Braggio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Sebag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rafael Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Winship Cancer Institute, Emory University, B3307 Clifton Road, Atlanta, GA, 30322, USA

    Sagar Lonial MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Braggio, E., Sebag, M., Fonseca, R. (2008). Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-564-0_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-82-4

  • Online ISBN: 978-1-59745-564-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation